2-[4-isopropyloxy-2-[4-methyl-2-(1-naphthyl)pentanoyl amino]phenylmethyl]benzoic Acid | 357606-98-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-[4-isopropyloxy-2-[4-methyl-2-(1-naphthyl)pentanoyl amino]phenylmethyl]benzoic Acid
• 英文别名: 2-[[2-[(4-Methyl-2-naphthalen-1-ylpentanoyl)amino]-4-propan-2-yloxyphenyl]methyl]benzoic acid
• CAS: 357606-98-5
• 化学式: C₃₃H₃₅NO₄
• 分子量: 509.645
• InChiKey: IDRAUZYCMUHDDR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.9
• 重原子数：
  38
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Benzoic acid derivatives, processes for producing the same and drugs containing the same as the active ingredient
  申请人：——

  公开号：US20030114435A1

  公开（公告）日：2003-06-19

  An agent comprising the benzoic acid of formula (I) 1 , wherein A, B, R 6 , R 7 are carbocyclic ring, heterocyclic ring, etc.; R 1 is hydroxy etc.; R 2 , R 3 , R 4 are alkyl etc.; R 5 , D, E are alkylene, etc.; G is oxygen etc., as active ingredient. The compound of formula (I) is considered to be useful for the treatment and/or prophylaxis of bone diseases, cancer, systemic granuloma, immunological diseases, allergy, atopy, asthma, gumboil, gingivitis, periodontitis, neurocyte death, Alzheimer's diseases, lungs injury, pulmopathy, acute hepatitis, nephritis, myocardial ischemia, Kawasaki disease, ambustion, ulcerative colitis, Crohn's disease, multiple organ failure, sleeping disorder, platelet aggregation, etc.

  一种代理剂，包括公式（I）中的苯甲酸，其中A、B、R6、R7是碳环、杂环等；R1是羟基等；R2、R3、R4是烷基等；R5、D、E是烷基等；G是氧等，作为活性成分。 公式（I）的化合物被认为对骨疾病、癌症、全身性肉芽肿、免疫性疾病、过敏、特应性皮炎、哮喘、牙龈炎、牙龈炎、牙周炎、神经细胞死亡、阿尔茨海默病、肺部损伤、肺病、急性肝炎、肾炎、心肌缺血、川崎病、烧伤、溃疡性结肠炎、克罗恩病、多器官功能衰竭、睡眠障碍、血小板聚集等疾病的治疗和/或预防具有用处。
• Benzoic acid derivatives and pharmaceutical agents comprising the same as active ingredient
  申请人：——

  公开号：US20040002493A1

  公开（公告）日：2004-01-01

  A pharmaceutical composition, which comprises a benzoic acid derivative of formula (I) 1 wherein R 1 is COOH, COOR 6 etc.; A, B is carbocyclic ring or heterocyclic ring; R 2 is alkyl, alkenyl, alkynyl etc.; R 4 is alkyl, cycloalkyl etc.; R 5 is carbocyclic ring or heterocyclic ring; or non-toxic salts thereof. The compound of the formula (I) can bind to Prostaglandin E 2 receptors, especially, EP 3 receptor and/or EP 4 receptor and show the antagonizing activity, and useful for the prevention and/or treatment of disease, for example, pain, allergy, Alzheimer's disease, cancer.

  一种药物组合物，包括化学式(I)1中的苯甲酸衍生物，其中R1为COOH，COOR6等；A、B为碳环或杂环；R2为烷基、烯基、炔基等；R4为烷基、环烷基等；R5为碳环或杂环；或其非毒性盐。化合物的化学式(I)可以与前列腺素E2受体结合，特别是EP3受体和/或EP4受体，并显示拮抗活性，对于预防和/或治疗疾病，例如疼痛、过敏、阿尔茨海默病、癌症等具有用处。
• Benzoic acid derivatives, processes for the preparation thereof and pharmaceutical agents comprising the same as active ingredient
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：US20040127487A1

  公开（公告）日：2004-07-01

  An agent comprising the benzoic acid of formula (I) 1 , wherein A, B, R 6 , R 7 are carbocyclic ring, heterocyclic ring, etc.; R 1 is hydroxy etc.; R 2 , R 3 , R 4 are alkyl etc.; R 5 , D, E are alkylene, etc.; G is oxygen etc., as active ingredient. The compound of formula (I) is considered to be useful for the treatment and/or prophylaxis of bone diseases, cancer, systemic granuloma, immunological diseases, allergy, atopy, asthma, gumboil, gingivitis, periodontitis, neurocyte death, Alzheimer's diseases, lungs injury, pulmopathy, acute hepatitis, nephritis, myocardial ischemia, Kawasaki disease, ambustion, ulcerative colitis, Crohn's disease, multiple organ failure, sleeping disorder, platelet aggregation, etc.

  本发明涉及一种代理人，其包含式（I）的苯甲酸，其中A，B，R6，R7是碳环，杂环等；R1是羟基等；R2，R3，R4是烷基等；R5，D，E是烷基等；G是氧等，作为活性成分。式（I）的化合物被认为对于骨疾病、癌症、全身性肉芽肿、免疫性疾病、过敏、特应性皮炎、哮喘、牙疳、牙龈炎、牙周炎、神经细胞死亡、阿尔茨海默病、肺损伤、肺病、急性肝炎、肾炎、心肌缺血、川崎病、烧伤、溃疡性结肠炎、克罗恩病、多器官衰竭、睡眠障碍、血小板聚集等的治疗和/或预防具有有用性。
• BENZOIC ACID DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1258473A1

  公开（公告）日：2002-11-20

  An agent comprising the benzoic acid of formula (I) , wherein A, B, R6, R7 are carbocyclic ring, heterocyclic ring, etc.; R1 is hydroxy etc.; R2, R3, R4 are alkyl etc.; R5, D, E are alkylene, etc.; G is oxygen etc., as active ingredient. The compound of formula (I) is considered to be useful for the treatment and/or prophylaxis of bone diseases, cancer, systemic granuloma, immunological diseases, allergy, atopy, asthma, gumboil, gingivitis, periodontitis, neurocyte death, Alzheimer's diseases, lungs injury, pulmopathy, acute hepatitis, nephritis, myocardial ischemia, Kawasaki disease, ambustion, ulcerative colitis, Crohn's disease, multiple organ failure, sleeping disorder, platelet aggregation, etc.

  一种包含式（I）苯甲酸的制剂 其中 A、B、R6、R7 为碳环、杂环等；R1 为羟基等；R2、R3、R4 为烷基等；R5、D、E 为亚烷基等；G 为氧等作为活性成分。 式（I）化合物被认为可用于治疗和/或预防骨病、癌症、全身性肉芽肿、免疫性疾病、过敏、过敏性疾病、哮喘、牙龈炎、牙周炎、神经细胞死亡、老年痴呆症、哮喘、牙龈肿胀、牙龈炎和牙周炎、阿尔茨海默病、肺损伤、肺病、急性肝炎、肾炎、心肌缺血、川崎病、伏灸、溃疡性结肠炎、克罗恩病、多器官衰竭、睡眠障碍、血小板聚集等。
• BENZOIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1314719A1

  公开（公告）日：2003-05-28

  A pharmaceutical composition, which comprises a benzoic acid derivative of formula (I) wherein R1 is COOH, COOR6 etc.; A, B is carbocyclic ring or heterocyclic ring; R2 is alkyl, alkenyl, alkynyl etc.; R4 is alkyl, cycloalkyl etc.; R5 is carbocyclic ring or heterocyclic ring; or non-toxic salts thereof. The compound of the formula (I) can bind to Prostaglandin E2 receptors, especially, EP3 receptor and/or EP4 receptor and show the antagonizing activity, and useful for the prevention and/or treatment of disease, for example, pain, allergy, Alzheimer' s disease, cancer.

  一种药物组合物，它包括式 (I) 的苯甲酸衍生物 其中 R1 是 COOH、COOR6 等；A、B 是碳环或杂环；R2 是烷基、烯基、炔基等；R4 是烷基、环烷基等；R5 是碳环或杂环； 或其无毒盐。 式（I）化合物可与前列腺素 E2 受体，特别是 EP3 受体和/或 EP4 受体结合，显示出拮抗活性，可用于预防和/或治疗疾病，例如疼痛、过敏、老年痴呆症、癌症。